American Association for Cancer Research
10780432ccr192935-sup-228606_3_supp_6088352_q5lzng.pptx (265.52 kB)

Supplemental Figure 1 from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial

Download (265.52 kB)
posted on 2023-03-31, 22:05 authored by Cesar A. Santa-Maria, Janelle W. Coughlin, Dipali Sharma, Mary Armanios, Amanda L. Blackford, Colleen Schreyer, Arlene Dalcin, Ashley Carpenter, Gerald J. Jerome, Deborah K. Armstrong, Madhu Chaudhry, Gary I. Cohen, Roisin M. Connolly, John Fetting, Robert S. Miller, Karen L. Smith, Claire Snyder, Andrew Wolfe, Antonio C. Wolff, Chiung-Yu Huang, Lawrence J. Appel, Vered Stearns

Change in waist circumference from baseline to six-months in patients assigned to POWER-remote and self-directed arms.


Breast Cancer Research Foundation

Cigarette Restitution Fund

National Institutes of Health



We initiated a clinical trial to determine the proportion of breast cancer survivors achieving ≥5% weight loss using a remotely delivered weight loss intervention (POWER-remote) or a self-directed approach, and to determine the effects of the intervention on biomarkers of cancer risk including metabolism, inflammation, and telomere length. Women with stage 0–III breast cancer, who completed local therapy and chemotherapy, with a body mass index ≥25 kg/m2 were randomized to a 12-month intervention (POWER-remote) versus a self-directed approach. The primary objective was to determine the number of women who achieved at least 5% weight loss at 6 months. We assessed baseline and 6-month change in a panel of adipocytokines (adiponectin, leptin, resistin, HGF, NGF, PAI1, TNFα, MCP1, IL1β, IL6, and IL8), metabolic factors (insulin, glucose, lipids, hs-CRP), and telomere length in peripheral blood mononuclear cells. From 2013 to 2015, 96 women were enrolled, and 87 were evaluable for the primary analysis; 45 to POWER-remote and 42 to self-directed. At 6 months, 51% of women randomized to POWER-remote lost ≥5% of their baseline body weight, compared with 12% in the self-directed arm [OR, 7.9; 95% confidence interval (CI), 2.6–23.9; P = 0.0003]; proportion were similar at 12 months (51% vs 17%, respectively, P = 0.003). Weight loss correlated with significant decreases in leptin, and favorable modulation of inflammatory cytokines and lipid profiles. There was no significant change in telomere length at 6 months. A remotely delivered weight loss intervention resulted in significant weight loss in breast cancer survivors, and favorable effects on several biomarkers.

Usage metrics

    Clinical Cancer Research



    Ref. manager